Dabrafenib (Tafinlar®)/trametinib (Mekinist®) is a BRAF/MEK combination therapy. Dabrafenib is an inhibitor of some mutated forms of BRAF kinase, and trametinib is a MEK1 and MEK2 inhibitor. About half of patients with melanoma have a mutated form of the BRAF protein in their tumors. Combination MEK/BRAF inhibitor therapy is associated with superior tumor response and patient survival compared with single-agent BRAF inhibitor therapy. Use of the combination also decreases the high rates of secondary cutaneous malignancies associated with single-agent BRAF inhibitory therapy.

Dabrafenib/trametinib combination therapy received its initial FDA approval for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations. More recently, 1 year of adjuvant therapy of the combination BRAF/MEK inhibitor therapy was found to significantly improve relapse-free survival and have a clinically meaningful benefit on overall survival as compared with placebo. In April 2018, dabrafenib/trametinib received an additional FDA approval for adjuvant treatment of patients with completely resected stage III melanoma with BRAF V600E or V600K mutations.

This document is part of an overall nursing toolkit intended to assist nurses in optimizing management of melanoma in patients receiving newer anti-melanoma therapies.
Both dabrafenib and trametinib are orally administered drugs.

For unresectable or metastatic melanoma (and at the full dose), dabrafenib 150 mg is taken twice daily (once in the morning and once in the evening, 12 hours between doses) for a total daily dosage of 300 mg. Trametinib 2 mg is taken once daily at the same time each day, preferably with either the morning or evening dose of dabrafenib (see left diagram). Dabrafenib trametinib treatment should continue until disease progression or unacceptable toxicity occurs.

For adjuvant treatment, dabrafenib is also dosed at 150 mg twice daily for a maximum total daily dosage of 300 mg. Trametinib 2 mg is taken once daily at the same time each day. The regimen is continued until disease recurrence or unacceptable toxicity for up to 1 year (see right diagram).

- Dabrafenib trametinib and dabrafenib should be administered on an empty stomach at least 1 hour before or at least 2 hours after eating. Dabrafenib capsules should not be opened, crushed, or broken.
- Dabrafenib should be stored at room temperature.
- Trametinib must be kept refrigerated.
  - Instruct patients to store trametinib in a refrigerator in the original bottle with the lid closed tightly to protect the medication from heat, light, or moisture.
  - Patients who are traveling should keep trametinib in a refrigerated lunch pack.
  - Temperature excursion data show that trametinib (in an opened bottle) is not damaged by storage outside the refrigerator for as many as 30 days if it is maintained at a temperature below 86°F (30°C). Nurses may advise patients who have inadvertently left trametinib out of the refrigerator to simply keep the medication cool and return it to the refrigerator as soon as possible.
- Concurrent administration of strong inhibitors of CYP3A4 or CYP2C8 should be avoided with dabrafenib. Also, dabrafenib is an inducer of CYP3A4, CYP2C8, and several other CYP enzymes; concomitant use of drugs that are sensitive substrates of these CYP enzymes may result in loss of efficacy of these drugs (example, hormonal contraceptives and proton pump inhibitors).
Possible treatment-related adverse events (AEs) should be discussed with patients prior to initiating trametinib/dabrafenib therapy. Patients should be informed of the importance of immediately reporting any health changes that may reflect a treatment-related AE.

AEs associated with trametinib/dabrafenib therapy can be generally divided into those that are most common (but typically mild-to-moderate in severity) and less common but serious AEs. Table 1 shows the common and less common but serious AEs associated with dabrafenib/trametinib as well as other AEs (Appendices 1 and 2).

### Table 1. AEs Associated With Dabrafenib/Trametinib

<table>
<thead>
<tr>
<th>Category</th>
<th>Examples</th>
<th>Treatment guidance (Appendix number)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Most common</td>
<td>Fever/pyrexia, Skin toxicities (rash), Hypertension, Chills, Cough, Headache, Peripheral edema, Arthralgia/myalgia, Anorexia, Gastrointestinal (Constipation/abdominal pain, Nausea/vomiting)</td>
<td>1, 2, 2, 2, 2, 2, 2, 2</td>
</tr>
<tr>
<td>Less common but serious</td>
<td>New primary cancers, Cutaneous (eg, basal cell or squamous cell carcinoma, keratoacanthoma, new melanoma), Non-cutaneous, Ocular toxicity, Cardiovascular (Cardiomyopathy, Hemorrhage, Venous thromboembolism, Hemolytic anemia, Colitis and gastrointestinal perforation, Interstitial lung disease/pneumonitis, Renal toxicity)</td>
<td>1, 1, 1, 2, 2, 2, 2, 2</td>
</tr>
</tbody>
</table>
Severe and sometimes moderate AEs are commonly managed by dose interruptions or withdrawal. In certain cases, referral to a cardiology, dermatology, or ophthalmology specialist is warranted.

Table 2: Recommended dose reductions for trametinib and dabrafenib

<table>
<thead>
<tr>
<th>Dabrafenib</th>
<th>Dose reduction from 150 mg orally twice daily to</th>
</tr>
</thead>
<tbody>
<tr>
<td>First dose reduction . . .</td>
<td>100 mg orally twice daily</td>
</tr>
<tr>
<td>Second dose reduction . .</td>
<td>75 mg orally twice daily</td>
</tr>
<tr>
<td>Third dose reduction . . .</td>
<td>50 mg orally twice daily</td>
</tr>
<tr>
<td>Subsequent . . .</td>
<td>Permanently discontinue if unable to tolerate 50 mg orally twice daily</td>
</tr>
<tr>
<td>Trametinib</td>
<td>Dose reduction from 2 mg once daily to</td>
</tr>
<tr>
<td>First dose reduction . . .</td>
<td>1.5 mg orally once daily</td>
</tr>
<tr>
<td>Second dose reduction . .</td>
<td>1 mg orally once daily</td>
</tr>
<tr>
<td>Subsequent modification . .</td>
<td>Permanently discontinue if unable to tolerate 1 mg orally once daily</td>
</tr>
</tbody>
</table>
**CLINICAL PEARLS**

- Before beginning targeted therapy, patients who previously received immunotherapy should be monitored carefully for possible overlapping toxicities. Several AEs are observed with both targeted and immunotherapy and may result in cumulative toxicities.

- Potential drug-drug interactions are an important component of dabrafenib/trametinib therapy for melanoma.
  - Dabrafenib is metabolized by CYP 3A4 and 2C8 and also induces CYP3A4 2C8 and several other enzyme systems. Therefore, dabrafenib efficacy can be reduced by other concomitantly administered agents sharing metabolic pathways. It can also lower the concentrations and efficacy of concomitant drugs as well.

- Patients should be seen by a dermatologist before beginning treatment, every 2 months during treatment, and as many as 7 months after treatment discontinuation.

- New skin cancers often initially present as a new wart, skin sore or reddish bump that bleeds or does not heal, and/or as a change in size or color of a mole. Patients should be made aware of this association and advised to immediately report any skin changes to the healthcare team.

- Advise patients to take pictures of any skin lesions for documentation.
Q. How long do the fevers last?

A. During the trials, pyrexia with BRAF/MEK inhibitor therapy occurred in about two thirds of patients. Fevers usually start after about 30 days of treatment, lasting 2-3 days, and typically improving after 6 months. Your patient must contact the oncology team if they begin to experience fevers. For low-grade fevers of 99-101°F, they can take antipyretics as directed by the provider. Also make sure your patient is drinking plenty of water. For a fever higher than 101°F, the oncology team member most likely will hold the BRAF inhibitor, and if the patient’s temperature is higher than 104°F, he/she will hold both medications and see the patient in clinic. The patient might need supportive care such as IV hydration and to begin low dose prednisone as recommended by the prescribing information. Some patients might need a dose holiday and dose reduction until fevers resolve. Keeping well hydrated is very important, especially with higher temperatures, to avoid dehydration.

Q. How long will the patient be on BRAF/MEK inhibitor therapy?

A. In the unresectable or metastatic disease setting, likely patients will continue therapy if their disease is responding to therapy and they are tolerating the medications. During the clinical trials, the patients who had to stop therapy were those who had disease progression or had moderate-to-severe drug toxicities who affected their quality of life and required persistent drug holidays, dose reduction, or discontinuation.

In the adjuvant setting, patients will continue therapy for a duration of 1 year, as long as their disease has not recurred and they are tolerating the medications. During the clinical trials, the patients who had to stop therapy were those who had disease recurrence or had moderate-to-severe drug toxicities that affected their quality of life and required persistent drug holidays, dose reduction, or discontinuation.
Financial Assistance
Resources from Novartis
Novartis Patient Assistance Program (financial and other support)
1-800-282-7630
www.us.tafinlarmekinist.com/advanced-melanoma

Additional Information Resources
AIM at Melanoma Foundation (Nurse on Call, patient symposia, drug resources, etc)
http://www.AIMatMelanoma.org
American Cancer Society: Targeted therapy for melanoma skin cancer
ADDITIONAL RESOURCES


- How to Take Tafinlar + Mekinist. Available at: https://www.us.tafinlarmekinist.com/advanced-melanoma/about-treatment/dosing-and-administration/.


The CSPs for pyrexia, skin toxicity, cardiotoxicity, and ocular toxicities referenced here are housed in the CSP section of the MNI website (TheMelanomaNurse.org).

They are not dabrafenib/trametinib specific (ie, they discuss all the relevant BRAF/MEK inhibitors).

Please click the link below to access the CSPs, which can also be printed from the site:

http://themelanomanurse.org/care-step-pathways/
APPENDIX 2
### Detection and management of AEs and laboratory abnormalities not included in Care Step Pathways for trametinib/dabrafenib

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Common symptoms</th>
<th>Common management/anticipatory guidance*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anorexia</td>
<td>Decreased appetite (occurs at higher rates in elderly patients)</td>
<td>* Monitor weight; query patient about appetite/eating habits; advise dietary modification if necessary</td>
</tr>
<tr>
<td></td>
<td></td>
<td>* Anticipate treatment hold for intolerable Grade 2 (oral intake altered) or Grade 3/4 (significant weight loss or malnutrition or life-threatening consequences)</td>
</tr>
<tr>
<td>Arthralgias/myalgias</td>
<td>Joint pain swelling, or stiffness, feeling tired</td>
<td>* Query patients regarding joint symptoms; standard supportive care (analgesia and anti-inflammatory drugs)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>* Anticipate treatment hold for intolerable Grade 2 (moderate pain, limiting instrumental ADLs) or Grade 3 (severe pain and self-care ADL limitations)</td>
</tr>
<tr>
<td>Chills</td>
<td>Shaking feeling/cold in absence of fever</td>
<td>* Query about symptoms, including symptoms related to serious febrile reactions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>* Anticipate treatment hold for intolerable Grade 2 (moderate tremors) or Grade 3 (severe or prolonged chills that are not responsive to narcotics)</td>
</tr>
<tr>
<td>Constipation/Abdominal pain</td>
<td>Infrequent stools/difficulty stooling, abdominal pain</td>
<td>* Increase fluid; fiber; laxatives. Consider appropriate testing to evaluate bowel obstruction</td>
</tr>
<tr>
<td></td>
<td></td>
<td>* Anticipate treatment hold for intolerable Grade 2 (persistent symptoms of constipation or moderate pain limiting instrumental ADLs) or Grade 3/4 (obstipation with manual evacuation indicated, severe abdominal pain, or life-threatening consequences)</td>
</tr>
<tr>
<td>Cough</td>
<td>Dry cough, shortness of breath, DOE</td>
<td>* Advise patients to report any symptoms; rule out infectious causes and pneumonitis (interstitial lung disease); monitor oxygen saturation (pulse oximetry) and consider chest x-ray; standard supportive care</td>
</tr>
<tr>
<td></td>
<td></td>
<td>* Anticipate treatment hold for intolerable Grade 2 (moderate symptoms, limiting instrumental ADLs) or Grade 3 (severe symptoms)</td>
</tr>
<tr>
<td>Deep vein thrombosis</td>
<td>Swelling, leg pain, shortness of breath</td>
<td>* Advise patients to seek medical care if they have acute onset arm/leg swelling</td>
</tr>
<tr>
<td></td>
<td></td>
<td>* Anticipate treatment hold of trametinib for Grade 2 (uncomplicated DVT) and permanent discontinuation if not improved after 3 weeks; no dose modification for dabrafenib for uncomplicated venous thromboembolism</td>
</tr>
<tr>
<td>Adverse event</td>
<td>Common symptoms</td>
<td>Common management/anticipatory guidance*</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>------------------------------------------------------</td>
<td>------------------------------------------</td>
</tr>
</tbody>
</table>
| Edema                               | Swelling of limbs, etc                                | • Occurs at higher rates in elderly patients. Advise patients to report swelling; standard supportive care; cardiac workup may be indicated  
• Anticipate treatment hold for intolerable Grade 2 (moderate swelling, limiting instrumental ADLs) or Grade 3 (severe swelling, gross deviation from anatomic contour) |
| Embryo-fetal toxicity               | —                                                    | • Trametinib/dabrafenib can cause fetal harm. Females and males of child-bearing potential should use effective nonhormonal birth control during trametinib/dabrafenib treatment and for 4 months after stopping trametinib/dabrafenib treatment |
| Fatigue                             | Unrelenting exhaustion not relieved by rest          | • Query patients regarding energy level; evaluate possible contributory factors, including infection, disease progression, and hematological and biochemical abnormalities; standard supportive care  
• Anticipate treatment hold for fatigue not relieved by rest and limiting ADLs (Grade 2/3) |
| Headache                            | Pain and/or change in vision                          | • May be multifactorial. For severe or persistent symptoms, consider other causes such as bleeding in the brain, uncontrolled hypertension, dehydration, new CNS disease, or other causes; consider brain MRI and evaluations for hypertension  
• Anticipate treatment hold for intolerable Grade 2 (moderate pain) or Grade 3 (severe pain, limiting self-care ADLs) |
| Hemolytic anemia (in patients with G6PD deficiency) | Yellow skin, weakness or dizziness, shortness of breath | • Monitor patients with G6PD deficiency for signs of hemolytic anemia. Advise patients to report any symptoms |
| Hemorrhage                          | Red or black/tarry stools; blood in urine; headaches; coughing or vomiting blood; abdominal pain; unusual vaginal bleeding; fatigue; dizziness or weakness | • Standard supportive care; medical intervention as indicated  
• Anticipate treatment hold for intolerable Grade 2 (moderate bleeding) or Grade 3/4 (severe bleeding requiring transfusion or radiologic, endoscopic, or operative intervention or life-threatening consequences) |
### Detection and management of AEs and laboratory abnormalities not included in Care Step Pathways for trametinib/dabrafenib (Continued)

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Common symptoms</th>
<th>Common management/anticipatory guidance*</th>
</tr>
</thead>
</table>
| **Hyperglycemia**                 | Fatigue, polyuria, polydipsia, headaches                                        | • Monitor fasting glucose/Hemoglobin A1C (particularly in patients with pre-existing diabetes/hyperglycemia); advise patients to report increased thirst/increased urination; provide anti-diabetic medication  
• Anticipate treatment hold for intolerable Grade 2 (fasting glucose >160 to 250 mg/dL) or Grade 3/4 (fasting glucose >250 mg/dL) |
| **Nausea/Vomiting**               | Vomiting, queasiness, RUQ or LUQ pain                                           | • For most cases, standard supportive care will be adequate  
• May indicate hepatotoxicity; check LFTs/lipase/amylase  
• Anticipate treatment hold for intolerable Grade 2 (oral intake decreased or 3-5 episodes vomiting in 24 hours) or Grade 3/4 (inadequate oral intake or ≥6 episodes vomiting in 24 hours or life-threatening consequences) |
| **Pulmonary embolism**           | Shortness of breath/chest pain                                                  | • Advise patients to seek medical care if they have shortness of breath, chest pain; appropriate workup, including imaging and CT angiogram  
• Anticipate treatment hold of trametinib and permanent discontinuation if not improved after 3 weeks or for life-threatening PE  
• Anticipate treatment hold of dabrafenib and permanent discontinuation if no recovery to Grade 0-1  
• Anticipate anticoagulant therapy for at least 6 months |
| **Pneumonitis** (interstitial lung disease) | New cough, dyspnea, hypoxia, pleural effusion or infiltrates                     | • Advise patients to report any new or worsening symptoms of lung or breathing problems (shortness of breath/cough)  
• Anticipate permanent discontinuation of trametinib; do not modify the dose of dabrafenib |
| **Renal toxicity**                | Decreased urine, blood in urine, swelling of ankles, decrease in appetite      | • Measure serum creatinine before treatment initiation and periodically during treatment; monitor kidney function  
• Anticipate treatment hold with intolerable Grade 2 (eGFR or CrCl 59 to 30 mL/min/1.73 m²) or Grade 3/4 (eGFR or CrCl ≤29 mL/min/1.73 m²) |

*When treatment holds are required, resume therapy at a lower dose level following improvement to Grade 0 to 1. Permanently discontinue targeted therapies in case of persistent intolerable Grade 2 events, persistent Grade 3 events, and persistent or recurrent Grade 4 events unless otherwise specified.